Mammalian transient protein expression and purification

• Use suspension-adapted mammalian host cells such as HEK293F, HEK293S, HEK293E/HEK293-EBNA1, Expi293F, or CHO cells according to the target protein and cited expression system.

• Use serum-free mammalian culture medium, expression plasmid DNA, and PEI-mediated transfection when following the HEK293E/HEK293-EBNA1 or CHO transient-expression approaches reported in the literature.

• Use expression constructs containing appropriate mammalian regulatory elements, secretion signals, affinity tags, Fc fusions, GFP fusions, His tags, Strep tags, or trimerization domains only when these features match the target-protein design and purification strategy.

• Maintain mammalian suspension cells in serum-free culture and use cells in a condition suitable for transient transfection, because the cited protocols depend on actively growing HEK293 or CHO cultures for plasmid-mediated recombinant protein production.

• Prepare endotoxin-controlled plasmid DNA encoding the target protein and its selected tag or fusion partner, because transient expression yield and purification depend on the expression vector, regulatory elements, secretion design, and affinity handle.

• Prepare PEI-DNA complexes for PEI-based transfection when using protocols based on HEK293E/HEK293-EBNA1 or CHO transient gene expression.

• Seed suspension mammalian cells, transfect with the selected expression plasmid using the literature-supported PEI-based or platform-specific transient-expression method, and culture the cells for the reported post-transfection expression window before harvest.

• For secreted proteins, collect culture supernatant after expression, clarify it by centrifugation or filtration, and purify the recombinant protein using the affinity method matching the engineered tag or Fc domain.

• For membrane proteins, harvest cells, prepare membrane fractions, solubilize the target protein, and purify using affinity chromatography followed by size-exclusion chromatography when required for biochemical or structural analysis.

• For proteins requiring oligomeric quality control, such as trimeric spike ectodomain examples, evaluate purified material by chromatography-based homogeneity assessment after affinity purification.

• Assess expression and purification success by combining yield measurement with SDS-PAGE, immunoblotting or ELISA, fluorescence when GFP-tagged constructs are used, activity assays when available, and size-exclusion chromatography for oligomeric state or aggregation analysis.

• Use negative controls such as mock-transfected or empty-vector cells and positive controls such as previously expressed tagged proteins when the assay format requires comparison of expression, purification recovery, or detection specificity.

Low recovered protein yield:

• Possible cause: vector architecture, host-cell system, transfection process, or culture conditions being suboptimal.
• Literature-supported solution: compare expression vectors and regulatory elements, optimize PEI-based transfection conditions, and select a HEK293 or CHO platform already shown to express the target class.

Secreted protein is detectable but purification recovery is poor:

• Possible cause: the construct design or affinity handle not matching the purification workflow.
• Literature-supported solution: use an affinity tag or Fc fusion compatible with the target protein and purification resin, then verify recovery by SDS-PAGE, ELISA, or tag-based detection.

Membrane-protein expression is weak or difficult to optimize:

• Possible cause: that membrane proteins often require construct, transfection, and harvest-time optimization.
• Literature-supported solution: screen expression using GFP-tagged membrane-protein constructs and optimize transfection and cultivation time before large-scale purification.

Purified protein shows heterogeneity:

• Possible cause: glycosylation state, oligomeric state, or construct format affecting biochemical homogeneity.
• Literature-supported solution: use chromatography-based polishing and select constructs or host systems reported to improve glycoprotein or oligomeric protein quality.